Proteomics International Outlines Roadmap for Four Commercial Diagnostic Tests
Proteomics International outlines disciplined commercial roadmap in April 2026 investor presentation
In its April 2026 investor presentation, Proteomics International Laboratories (ASX: PIQ) outlined a structured commercial plan designed to convert years of research into revenue-generating operations. Management detailed how the company is advancing a portfolio of four prognostic and diagnostic tests through defined development phases whilst maintaining strict capital discipline. The presentation positioned the distributor partnership model as the chosen go-to-market strategy for both Australia and the USA, addressing a recurring investor concern around biotech companies transitioning from R&D to revenue generation. Testing operations are supported by NATA-certified laboratories in Australia and CLIA/CAP-accredited facilities in the USA.
The strategic framework centres on leveraging established clinical networks rather than building proprietary infrastructure, reducing operational risk and capital requirements. Management presented defined milestones through FY29, with near-term priorities including distributor appointments, validation completion for PromarkerEndo, and controlled market releases in Australia during FY27 H1.
When big ASX news breaks, our subscribers know first
Understanding proteomics-based diagnostics
Proteomics is the study of proteins that drive biological processes, including disease progression. Unlike genomics, which analyses DNA, proteomics examines the dynamic biochemical changes occurring in the body, offering distinct clinical insights into treatment response and disease activity. This approach supports prognosis, risk assessment, and clinical decision-making by identifying protein-level changes before symptoms manifest.
The technical complexity requires deep expertise. Protein levels fluctuate with disease stage, treatment protocols, and patient-specific factors. Results depend heavily on standardised sample handling, storage conditions, and rigorous analytical validation. This scientific foundation creates substantial barriers to entry and underpins the clinical validity of PIQ’s test portfolio. The company’s accredited laboratory operations in both Australia and the USA provide the regulated infrastructure required to deliver proteomics-based tests at commercial scale.
Four-test portfolio targets substantial addressable markets
Management highlighted four tests in commercial or late-stage development: PromarkerD (predicting diabetic kidney disease risk), PromarkerEso (detecting oesophageal cancer in reflux patients), PromarkerEndo (diagnosing endometriosis), and OxiDx (measuring oxidative stress). The presentation detailed Serviceable Obtainable Market (SOM) estimates representing realistic medium-term penetration across Australia and the USA.
| Test | Australia SOM (Annual Tests) | USA SOM (Annual Tests) |
|---|---|---|
| PromarkerD | 20,000 | 390,000 |
| PromarkerEso | 15,000 | 240,000 |
| PromarkerEndo | 50,000 | 360,000 |
The SOM figures account for realistic constraints including clinical pathway integration, workflow adoption, and reimbursement timelines. PromarkerD assumes testing once every four years for Type 2 diabetes patients in active care. PromarkerEso targets chronic reflux patients with appropriate risk factors tested every three years. PromarkerEndo addresses reproductive-age women entering active diagnostic work-up annually.
Clinical performance metrics
The presentation detailed key clinical performance statistics for each primary test, demonstrating the tests’ ability to reliably rule out disease:
- PromarkerD: 76–85% sensitivity, 92–95% specificity, NPV 95–97%, AUC 0.78–0.88. Multi-year validation completed.
- PromarkerEso: 91% sensitivity, 98% specificity, NPV 99.9%, AUC exceeding 0.98. Assay being validated across multiple cohorts.
- PromarkerEndo: 83% sensitivity, 95% specificity, NPV 75%, AUC exceeding 0.92. Assay being validated across independent cohorts.
High specificity and negative predictive value (NPV) figures are critical for clinical adoption and reimbursement approval. These metrics demonstrate the tests can accurately identify patients who do not have the condition, reducing unnecessary invasive procedures and downstream healthcare costs.
Distributor model designed for capital efficiency
The presentation outlined a distribution partnership approach, representing a strategic shift from earlier direct-to-consumer and hybrid models. Management highlighted five key advantages of the distributor-led strategy:
- Leverages existing clinician networks rather than building proprietary sales infrastructure
- Integrates testing into established clinical workflows and ordering systems
- Avoids capital-intensive proprietary infrastructure costs
- Reduces operational and compliance risks by partnering with proven platforms
- Creates a scalable, repeatable commercial model for geographic expansion
Under this framework, distributor partners manage market access, clinician engagement, sample collection, and logistics. PIQ retains control of the high-value testing function, performing all analyses in its accredited laboratories whilst maintaining quality control, regulatory compliance, and reporting standards. The model directly addresses capital burn concerns by outsourcing market access whilst preserving the economic value of proprietary testing.
Three-year execution roadmap through FY29
Management presented a phased timeline detailing near-term actions and medium-term objectives through FY29:
- FY26 H2 (Current): Discontinued direct-to-consumer model, engaged distribution partners, restructured leadership, commenced OxiDx strategic review.
- FY27 H1: Appoint Australian distributor, finalise PromarkerEndo validation, harmonise laboratory processes across jurisdictions, commence controlled market releases.
- FY27 H2: Appoint USA distributors, establish US-based team, prepare reimbursement dossiers for submission.
- FY28: Broaden distributor network coverage, expand laboratory capacity aligned with demand, publish clinical utility and health economic evidence.
- FY29: Enhance distributor performance management, expand product pipeline, improve operating leverage through streamlined operations.
The roadmap positions distributor appointments and controlled market launches as immediate priorities, with reimbursement submissions following initial revenue generation and real-world evidence accumulation.
Reimbursement pathway considerations
The presentation outlined dual-track reimbursement strategies reflecting different regulatory frameworks across markets. Australia operates a national reimbursement system managed by the Medical Services Advisory Committee (MSAC), which evaluates tests for Medicare Benefits Schedule (MBS) listing. The USA operates a decentralised model requiring engagement with Medicare (via the MolDX program), Medicaid, and multiple private payers.
PIQ’s approach initiates commercialisation through private pay channels to generate early revenue whilst building the clinical and health economic evidence base required for formal coverage submissions. PromarkerD has obtained a CMS Proprietary Laboratory Analysis (PLA) code in the USA, a procedural milestone for Medicare billing. Reimbursement timelines are long and outcomes uncertain, but management has structured the strategy to generate revenue during the evidence-building phase rather than waiting for coverage approval.
The next major ASX story will hit our subscribers first
Strategic priorities and path to sustainable value
Management outlined five enterprise priorities connecting scientific capabilities to commercial outcomes:
- Drive commercial execution through distributor-led market access, phased launches, and reimbursement engagement
- Innovate portfolio based on clear clinical needs with robust intellectual property protection
- Optimise operations by standardising systems, expanding laboratory capacity responsively, and strengthening quality control
- Build organisational capabilities through clear structures, disciplined performance management, and talent retention
- Deliver sustainable value by prioritising revenue growth, capital efficiency, proactive risk management, and long-term shareholder returns
The presentation emphasised capital discipline as a recurring theme, with the distributor model explicitly designed to minimise capital requirements whilst accelerating market access. Leadership restructuring during FY26 H2 was positioned as aligning management capabilities with commercial execution priorities.
The overarching investment thesis positions PIQ as executing a structured transition from research to commercial operations with defined milestones investors can track. The company is no longer primarily a research-focused organisation but is implementing a disciplined commercial framework designed to convert validated diagnostics into recurring revenue streams.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Get market-moving biotech announcements delivered straight to your inbox before the broader market reacts. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment ASX healthcare companies make critical announcements.